JP7109547B2 - 真核ゲノム修飾のための操作されたCas9システム - Google Patents

真核ゲノム修飾のための操作されたCas9システム Download PDF

Info

Publication number
JP7109547B2
JP7109547B2 JP2020531575A JP2020531575A JP7109547B2 JP 7109547 B2 JP7109547 B2 JP 7109547B2 JP 2020531575 A JP2020531575 A JP 2020531575A JP 2020531575 A JP2020531575 A JP 2020531575A JP 7109547 B2 JP7109547 B2 JP 7109547B2
Authority
JP
Japan
Prior art keywords
sequence
engineered
protein
cell
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020531575A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505180A (ja
Inventor
ティモシー・シーベック
フーチアン・チェン
グレゴリー・デイビス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Aldrich Co LLC
Original Assignee
Sigma Aldrich Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Aldrich Co LLC filed Critical Sigma Aldrich Co LLC
Publication of JP2021505180A publication Critical patent/JP2021505180A/ja
Priority to JP2022083820A priority Critical patent/JP7559005B2/ja
Application granted granted Critical
Publication of JP7109547B2 publication Critical patent/JP7109547B2/ja
Priority to JP2024114477A priority patent/JP2024161376A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C12N9/222Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
    • C12N9/226Class 2 CAS enzyme complex, e.g. single CAS protein
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/85Fusion polypeptide containing an RNA binding domain
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/21Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001Deoxyribonuclease I (3.1.21.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
JP2020531575A 2018-02-15 2019-02-15 真核ゲノム修飾のための操作されたCas9システム Active JP7109547B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022083820A JP7559005B2 (ja) 2018-02-15 2022-05-23 真核ゲノム修飾のための操作されたCas9システム
JP2024114477A JP2024161376A (ja) 2018-02-15 2024-07-18 真核ゲノム修飾のための操作されたCas9システム

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862631304P 2018-02-15 2018-02-15
US62/631,304 2018-02-15
US201862720525P 2018-08-21 2018-08-21
US62/720,525 2018-08-21
PCT/US2019/018335 WO2019161290A1 (en) 2018-02-15 2019-02-15 Engineered cas9 systems for eukaryotic genome modification

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022083820A Division JP7559005B2 (ja) 2018-02-15 2022-05-23 真核ゲノム修飾のための操作されたCas9システム

Publications (2)

Publication Number Publication Date
JP2021505180A JP2021505180A (ja) 2021-02-18
JP7109547B2 true JP7109547B2 (ja) 2022-07-29

Family

ID=65995829

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020531575A Active JP7109547B2 (ja) 2018-02-15 2019-02-15 真核ゲノム修飾のための操作されたCas9システム
JP2022083820A Active JP7559005B2 (ja) 2018-02-15 2022-05-23 真核ゲノム修飾のための操作されたCas9システム
JP2024114477A Pending JP2024161376A (ja) 2018-02-15 2024-07-18 真核ゲノム修飾のための操作されたCas9システム

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022083820A Active JP7559005B2 (ja) 2018-02-15 2022-05-23 真核ゲノム修飾のための操作されたCas9システム
JP2024114477A Pending JP2024161376A (ja) 2018-02-15 2024-07-18 真核ゲノム修飾のための操作されたCas9システム

Country Status (11)

Country Link
US (2) US10767193B2 (https=)
EP (1) EP3752607A1 (https=)
JP (3) JP7109547B2 (https=)
KR (3) KR102465067B1 (https=)
CN (1) CN111902536B (https=)
AU (3) AU2019222568B2 (https=)
BR (1) BR112020010479A2 (https=)
CA (2) CA3084020C (https=)
IL (2) IL321024A (https=)
SG (1) SG11202007382TA (https=)
WO (1) WO2019161290A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
US11111492B2 (en) * 2017-03-06 2021-09-07 Florida State University Research Foundation, Inc. Genome engineering methods using a cytosine-specific Cas9
KR20210045360A (ko) 2018-05-16 2021-04-26 신테고 코포레이션 가이드 rna 설계 및 사용을 위한 방법 및 시스템
EP3823633A4 (en) 2018-06-29 2023-05-03 Editas Medicine, Inc. SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO
US10913941B2 (en) 2019-02-14 2021-02-09 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
CA3129835A1 (en) 2019-02-15 2020-08-20 Sigma-Aldrich Co. Llc Crispr/cas fusion proteins and systems
CA3130789A1 (en) 2019-03-07 2020-09-10 The Regents Of The University Of California Crispr-cas effector polypeptides and methods of use thereof
WO2021127209A1 (en) 2019-12-17 2021-06-24 Sigma-Aldrich Co. Llc Genome editing in bacteroides
GB2594339B (en) * 2020-02-14 2023-02-08 Metagenomi Inc Enzymes with RUVC domains
CA3163463A1 (en) * 2020-03-11 2021-09-16 Fuqiang Chen High fidelity spcas9 nucleases for genome modification
GB2608292B (en) * 2020-03-31 2024-02-14 Metagenomi Inc Class II, type II CRISPR systems
CN112159801B (zh) * 2020-07-13 2022-11-15 复旦大学 SlugCas9-HF蛋白、含有SlugCas9-HF蛋白的基因编辑系统及应用
EP4230737A4 (en) * 2020-09-21 2024-07-24 Korea University Research and Business Foundation NOVEL IMPROVED BASIC EDITING OR REVISION FUSION PROTEIN AND USE THEREOF
JP2023549339A (ja) * 2020-11-06 2023-11-24 ペアワイズ・プランツ・サーヴィシズ,インコーポレイテッド 対立遺伝子の、rnaによりコードされるdna置換のための組成物および方法
CN113717960B (zh) * 2021-08-27 2023-07-18 电子科技大学 一种新Cas9蛋白、CRISPR-Cas9基因组定向编辑载体及基因组编辑方法
CA3225082A1 (en) 2021-08-27 2023-03-02 Brian C. Thomas Enzymes with ruvc domains
MX2024006257A (es) 2021-11-24 2024-07-29 Metagenomi Inc Sistemas de endonucleasas.
CN114657181B (zh) * 2022-04-01 2023-08-25 安徽大学 一种靶向H1.4的sgRNA以及H1.4基因编辑方法
CN119948064A (zh) * 2022-09-23 2025-05-06 庄伟哲 靶向整合素 αIIbβ3的含组织纤维溶酶原活化剂或其变异体的融合蛋白质及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015148863A2 (en) 2014-03-26 2015-10-01 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232430A1 (en) 2001-11-26 2003-12-18 Advanced Cell Technology Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
EP3241902B1 (en) * 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
EP3363902B1 (en) * 2012-12-06 2019-11-27 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
AU2013359262C1 (en) * 2012-12-12 2021-05-13 Massachusetts Institute Of Technology CRISPR-Cas component systems, methods and compositions for sequence manipulation
EP3004370B1 (en) 2013-06-05 2024-08-21 Duke University Rna-guided gene editing and gene regulation
US9074199B1 (en) * 2013-11-19 2015-07-07 President And Fellows Of Harvard College Mutant Cas9 proteins
JP2017503514A (ja) * 2014-01-24 2017-02-02 ノースカロライナ ステート ユニバーシティーNorth Carolina State University Cas9ターゲッティングをガイドする配列に関する方法および組成物
EP3633032A3 (en) * 2014-08-28 2020-07-29 North Carolina State University Novel cas9 proteins and guiding features for dna targeting and genome editing
WO2016054326A1 (en) * 2014-10-01 2016-04-07 The General Hospital Corporation Methods for increasing efficiency of nuclease-induced homology-directed repair
LT3604527T (lt) 2016-06-02 2021-06-25 Sigma-Aldrich Co., Llc Programuojamų, dnr surišančių baltymų panaudojimas tiksliniam genomo modifikavimui pagerinti
US10017760B2 (en) 2016-06-24 2018-07-10 Inscripta, Inc. Methods for generating barcoded combinatorial libraries
JP7305534B2 (ja) 2016-07-06 2023-07-10 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛関連障害を処置するための物質及び方法
JP7182545B2 (ja) * 2016-12-14 2022-12-02 ヴァーヘニンゲン ユニヴェルシテット 熱安定性cas9ヌクレアーゼ
KR102523217B1 (ko) * 2017-07-11 2023-04-20 시그마-알드리치 컴퍼니., 엘엘씨 표적된 게놈 변형을 개선하기 위한 뉴클레오솜 상호작용 단백질 도메인 사용
KR20200036912A (ko) * 2017-07-31 2020-04-07 리플렉션 바이오테크놀러지스 리미티드 안과 질환을 위한 세포 모델 및 치료요법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015148863A2 (en) 2014-03-26 2015-10-01 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bosma, E. F. et al.,"Complete genome sequence of thermophilic Bacillus smithii type strain DSM 4216(T)",Stand. Genomic. Sci.,2016年,Vol. 11; 52,pp. 1-11

Also Published As

Publication number Publication date
US20190249200A1 (en) 2019-08-15
CN111902536A (zh) 2020-11-06
US12297449B2 (en) 2025-05-13
KR102684890B1 (ko) 2024-07-12
EP3752607A1 (en) 2020-12-23
KR102465067B1 (ko) 2022-11-10
KR20230022258A (ko) 2023-02-14
AU2024202158A1 (en) 2024-05-02
BR112020010479A2 (pt) 2020-11-24
CA3084020A1 (en) 2019-08-22
AU2019222568B2 (en) 2021-10-14
JP2021505180A (ja) 2021-02-18
AU2019222568A1 (en) 2020-05-21
SG11202007382TA (en) 2020-08-28
JP2022122910A (ja) 2022-08-23
CN111902536B (zh) 2024-07-30
KR102494449B1 (ko) 2023-01-31
IL274528B1 (en) 2025-06-01
US10767193B2 (en) 2020-09-08
IL321024A (en) 2025-07-01
IL274528B2 (en) 2025-10-01
KR20220015502A (ko) 2022-02-08
US20200354752A1 (en) 2020-11-12
AU2022200130B2 (en) 2024-03-07
CA3281020A1 (en) 2026-03-02
JP7559005B2 (ja) 2024-10-01
IL274528A (en) 2020-06-30
KR20200121342A (ko) 2020-10-23
AU2022200130A1 (en) 2022-02-10
WO2019161290A1 (en) 2019-08-22
CA3084020C (en) 2025-11-25
JP2024161376A (ja) 2024-11-19

Similar Documents

Publication Publication Date Title
JP7559005B2 (ja) 真核ゲノム修飾のための操作されたCas9システム
JP7469285B2 (ja) 標的化されたゲノム修飾を増強するためのヌクレオソーム相互作用タンパク質ドメインの使用
JP2020530992A (ja) Crispr/casアクチベーターシステムのための合成ガイドrna
US20230287377A1 (en) Crispr/cas fusion proteins and systems
JP7629673B2 (ja) ゲノム改変のための高忠実度SpCas9ヌクレアーゼ
BR122025004697B1 (pt) Sistemas para modificar um genoma eucariótico, pluralidade de ácidos nucleicos, vetor, e proteína de fusão
BR122025004697A2 (pt) Sistema para modificar uma sequência cromossômica em uma célula eucariótica, pluralidade de ácidos nucleicos, vetor, célula eucariótica, proteína de fusão, composição e usos
HK40040051A (en) Engineered cas9 systems for eukaryotic genome modification
HK40040051B (zh) 用於真核基因组修饰的改造的cas9系统
HK40020657A (en) Using nucleosome interacting protein domains to enhance targeted genome modification

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220523

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220523

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220530

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220531

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220628

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220719

R150 Certificate of patent or registration of utility model

Ref document number: 7109547

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250